Fresenius Kabi announced that Arunesh Verma joined as the president of Fresenius Kabi USA and as a member of its global executive leadership team.
As a member of the executive leadership team, Verma reports to CEO Pierluigi Antonelli. He holds responsibility for the commercial operations of Fresenius Kabi in the U.S., succeeding John Ducker. Ducker intends to retire after a 35-year career with the company.
“I am very pleased to welcome Arunesh Verma to our company at a time when we are successfully executing our #Vision2026 transformation in line with #FutureFresenius, strengthening our commercial operations, and bringing online advanced new U.S. manufacturing capabilities – all designed to support U.S. caregivers,” Antonelli said in a news release. “At the same time, I want to thank John Ducker for his outstanding leadership and achievement over 35 years. His contributions have shaped our company’s growth and reputation in the U.S. in profound ways.”
Fresenius Kabi specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In the U.S., the company develops and manufactures injectable medicines and biosimilars used in hospitals and other sites of care.
Verma joins the company from Cipla, a global pharmaceutical company. There, he served as CEO of Cipla North America and a member of the company’s global management council. He began his career in sales roles with Novartis. Additionally, he worked at Cipla, Torrent Pharma, Sandoz and Dr. Reddy’s Laboratories.
“I am thrilled to join Fresenius Kabi, a highly respected global leader with an outstanding reputation in the U.S. and deep roots in health care worldwide,” Verma said. “Fresenius Kabi specializes in putting essential medicines and technologies in the hands of people who care for patients – and this is a purpose to which I have devoted my career of more than 22 years.”
